Drugdocs | Vyzulta®

Drug updated on 3/28/2024

Dosage Form	solution (topical ophthalmic: 0.24 mg/mL (0.024%))
Drug Class	Prostaglandin analogs
Ongoing and Completed Studies	ClinicalTrials.gov

Indication

Indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

Latanoprostene bunod ophthalmic solution (Vyzulta) is indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
A total of 106 trials were included in a systematic review/meta-analysis, providing data on 18,523 participants who used Vyzulta among other medications.
The study found that latanoprostene bunod was significantly more effective than unoprostone and most beta-blockers such as apraclonidine, betaxolol, brimonidine, brinzolamide, carteolol dorzolamide and timolo at reducing intraocular pressure.
When compared to other prostaglandin analogues (PGAs), latanoprostene bunod (LBN) numerically outperformed latanoprost and tafluprost but had similar performance to bimatoprost 0.01% in terms of lowering intraocular pressure.
However it was slightly less efficient than bimatopost 0.03%, which ranked first according to Surface under the cumulative ranking curve (SUCRA).
Despite this slight disadvantage against bimatropost 0.03%, overall, LBN's effectiveness placed it second after bimatropost 0.03% based on SUCRA rankings from the reviewed studies.

Document Title	Year	Source
Vyzulta (latanoprostene bunod ophthalmic solution) Prescribing Information.	2019	Bausch Health US, LLC, Bridgewater, NJ

Document Title	Year	Source
Short-term efficacy of latanoprostene bunod for the treatment of open-angle glaucoma and ocular hypertension: a systematic literature review and a network meta-analysis.	2022	British Journal of Ophthalmology
Clinical review report: latanoprost bunod (Vyzulta).	2019	CADTH

Document Title	Year	Source
Primary open-angle glaucoma PPP 2020.	2020	American Academy of Ophthalmology